DB:DMN

Stock Analysis Report

Executive Summary

Diamyd Medical AB (publ), a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes.

Rewards

Revenue is forecast to grow 36.71% per year

Risk Analysis

Makes less than USD$1m in revenue (SEK1M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

Shareholders have been diluted in the past year



Snowflake Analysis

Excellent balance sheet with limited growth.

Share Price & News

How has Diamyd Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DMN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

8.3%

DMN

0.4%

DE Biotechs

0.2%

DE Market


1 Year Return

169.8%

DMN

9.0%

DE Biotechs

14.4%

DE Market

Return vs Industry: DMN exceeded the German Biotechs industry which returned 9% over the past year.

Return vs Market: DMN exceeded the German Market which returned 14.4% over the past year.


Shareholder returns

DMNIndustryMarket
7 Day8.3%0.4%0.2%
30 Day-10.1%-2.1%0.9%
90 Day160.3%8.0%4.6%
1 Year169.8%169.8%9.2%9.0%17.9%14.4%
3 Yearn/a45.5%43.9%15.7%5.6%
5 Yearn/a12.8%10.5%23.4%6.5%

Price Volatility Vs. Market

How volatile is Diamyd Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Diamyd Medical undervalued compared to its fair value and its price relative to the market?

24.31x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DMN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DMN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DMN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: DMN is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DMN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DMN is overvalued based on its PB Ratio (24.3x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Diamyd Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

13.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: DMN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: DMN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: DMN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: DMN's revenue (36.7% per year) is forecast to grow faster than the German market (5% per year).

High Growth Revenue: DMN's revenue (36.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: DMN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Diamyd Medical performed over the past 5 years?

-15.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DMN is currently unprofitable.

Growing Profit Margin: DMN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DMN is unprofitable, and losses have increased over the past 5 years at a rate of -15.9% per year.

Accelerating Growth: Unable to compare DMN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DMN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: DMN has a negative Return on Equity (-62.27%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Diamyd Medical's financial position?


Financial Position Analysis

Short Term Liabilities: DMN's short term assets (SEK54.0M) exceed its short term liabilities (SEK9.5M).

Long Term Liabilities: DMN's short term assets (SEK54.0M) exceed its long term liabilities (SEK777.0K).


Debt to Equity History and Analysis

Debt Level: DMN is debt free.

Reducing Debt: DMN has not had any debt for past 5 years.


Balance Sheet

Inventory Level: DMN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if DMN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DMN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if DMN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Diamyd Medical's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate DMN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate DMN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DMN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DMN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DMN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.6yrs

Average board tenure


CEO

Ulf Hannelius (44yo)

3.8yrs

Tenure

kr2,167,000

Compensation

Mr. Ulf Hannelius, PhD, MBA, has been the Chief Executive Officer of Diamyd Medical AB (publ) since April 11, 2016 and serves as its President. Mr. Hannelius served as an Interim Chief Executive Officer at ...


CEO Compensation Analysis

Compensation vs Market: Ulf's total compensation ($USD221.20K) is below average for companies of similar size in the German market ($USD412.57K).

Compensation vs Earnings: Ulf's compensation has increased whilst the company is unprofitable.


Board Members

NamePositionTenureCompensationOwnership
David Leslie
Member of the Scientific Advisory Board21.1yrsno datano data
Lars Klareskog
Member of the Scientific Advisory Board24.1yrsno datano data
Daniel Kaufman
Member of The Scientific Advisory Board24.1yrsno datano data
Anders Essen-Möller
Director24.1yrskr1.02m14.3% SEK18.4m
Erik Nerpin
Chairman of the Board4.9yrskr197.00k0.059% SEK76.4k
Bart Roep
Member of the Scientific Advisory Board14.1yrsno datano data
Maria-Teresa Essen-Möller
Director7.1yrskr131.00k0.093% SEK119.1k
Bryndis Birnir
Member of The Scientific Advisory Board6.7yrsno datano data
Brooke Ligon
Member of The Scientific Advisory Board6.7yrsno datano data
Qinghua Wang
Member of The Scientific Advisory Board6.7yrsno datano data

10.6yrs

Average Tenure

66.5yo

Average Age

Experienced Board: DMN's board of directors are seasoned and experienced ( 10.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.7%.


Top Shareholders

Company Information

Diamyd Medical AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Diamyd Medical AB (publ)
  • Ticker: DMN
  • Exchange: DB
  • Founded: 1984
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: kr1.361b
  • Listing Market Cap: kr128.715m
  • Shares outstanding: 69.17m
  • Website: https://www.diamyd.com

Number of Employees


Location

  • Diamyd Medical AB (publ)
  • Kungsgatan 29
  • Stockholm
  • Stockholm County
  • 111 56
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
DMYD BOM (OMX Nordic Exchange Stockholm)YesSeries B SharesSESEKMay 2013
DMNDB (Deutsche Boerse AG)YesSeries B SharesDEEURMay 2013

Biography

Diamyd Medical AB (publ), a diabetes company, engages in the development of combination therapies for the treatment of autoimmune diabetes. The company’s products include Diamyd intralymphatic, a diabetes vaccine for antigen-specific immunotherapy for treating autoimmune diabetes, which is in Phase IIb clinical trial for DIAGNODE-2, and Phase IIa clinical trial for DIAGNODE-1; and Remygen, which is in Phase I/II ReGenerate-1 trial, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 diabetes. It also engages in development of Diamyd intralymphatic for the treatment of LADA and newly diagnosed. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was founded in 1984 and is based in Stockholm, Sweden. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/19 23:55
End of Day Share Price2020/02/19 00:00
Earnings2019/11/30
Annual Earnings2019/08/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.